Attempting to compensate for reduced neuronal nitric oxide synthase protein with nitrate supplementation cannot overcome metabolic dysfunction but rather has detrimental effects in dystrophin-deficient mdx muscle by Timpani, Cara A. et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Attempting to compensate for reduced neuronal nitric oxide synthase 
protein with nitrate supplementation cannot overcome metabolic 
dysfunction but rather has detrimental effects in dystrophin-deficient mdx 
muscle 
Citation:  
Timpani, Cara A., Trewin, Adam J., Stojanovska, Adam J., Robinson, Ainsley, Goodman, Craig 
A., Nurgali, Kulmira, Betik, Andrew C., Stepto, Nigel, Hayes, Alan, McConell, Glenn K. and 
Rybalka, Emma 2017, Attempting to compensate for reduced neuronal nitric oxide synthase 
protein with nitrate supplementation cannot overcome metabolic dysfunction but rather 
has detrimental effects in dystrophin-deficient mdx muscle, Neurotherapeutics, vol. 14, no. 
2, pp. 429-446. 
DOI: http://www.dx.doi.org/10.1007/s13311-016-0494-7 
 
 
   
© 2016, The Authors 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
Downloaded from DRO:  
http://hdl.handle.net/10536/DRO/DU:30109977 
 
ORIGINAL ARTICLE
Attempting to Compensate for Reduced Neuronal Nitric Oxide
Synthase Protein with Nitrate Supplementation Cannot
Overcome Metabolic Dysfunction but Rather Has Detrimental
Effects in Dystrophin-Deficient mdxMuscle
Cara A. Timpani1 & Adam J. Trewin2 & Vanesa Stojanovska1 & Ainsley Robinson1 &
Craig A. Goodman1,2,3 & Kulmira Nurgali1 & Andrew C. Betik1,2 & Nigel Stepto2 &
Alan Hayes1,2,3 & Glenn K. McConell2,3 & Emma Rybalka1,2,3
Published online: 5 December 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Duchenne muscular dystrophy arises from the loss of
dystrophin and is characterized by calcium dysregulation, mus-
cular atrophy, and metabolic dysfunction. The secondary reduc-
tion of neuronal nitric oxide synthase (nNOS) from the sarco-
lemma reduces NO production and bioavailability. As NO mod-
ulates glucose uptake, metabolism, and mitochondrial bioener-
getics, we investigated whether an 8-week nitrate supplementa-
tion regimen could overcome metabolic dysfunction in the mdx
mouse. Dystrophin-positive control (C57BL/10) and dystrophin-
deficient mdx mice were supplemented with sodium nitrate
(85 mg/l) in drinking water. Following the supplementation pe-
riod, extensor digitorum longus and soleus were excised and
radioactive glucose uptake was measured at rest (basal) and dur-
ing contraction. Gastrocnemius was excised and mitochondrial
respiration was measured using the Oroboros Oxygraph. Tibialis
anterior was analyzed immunohistochemically for the presence
of dystrophin, nNOS, nitrotyrosine, IgG and CD45+ cells, and
histologically to assess areas of damage and regeneration.
Glucose uptake in the basal and contracting states was normal
in unsupplemented mdx muscles but was reduced following
nitrate supplementation inmdxmuscles only. The mitochondrial
utilization of substrates was also impaired in mdx gastrocnemius
during phosphorylating and maximal uncoupled respiration, and
nitrate could not improve respiration in mdx muscle. Although
nitrate supplementation reduced mitochondrial hydrogen perox-
ide emission, it inducedmitochondrial uncoupling in red gastroc-
nemius, increased muscle fiber peroxynitrite (nitrotyrosine), and
promoted skeletal muscle damage. Our novel data suggest that
despite lower nNOS protein expression and likely lower NO
production inmdxmuscle, enhancingNOproductionwith nitrate
supplementation in these mice has detrimental effects on skeletal
muscle. Thismay have important relevance for thosewith DMD.
Keywords Duchennemuscular dystrophy . Nitrate
supplementation .Metabolism . Glucose uptake .
Mitochondria
Introduction
Duchenne muscular dystrophy (DMD) is a progressive X-
linked [1] neuromuscular disease affecting 1 in 3500 to 5000
live male births [2], which arises from the ablation of the
cytoskeletal protein, dystrophin [3]. Dystrophin deficiency
causes alterations to the myofiber architecture leading to
membrane lesions, calcium (Ca2+) accumulation, muscular
weakness, and cyclic bouts of degeneration and regeneration
until the regenerative capacity of the muscle is unable to
match demand for repair [4]. Damaged muscle is eventually
replaced with fibrous and/or fatty connective tissue leading to
a decrease in muscle function, with cardiorespiratory failure
ensuing by the third decade of life [5].
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Mitochondrial and metabolic dysfunction have been in-
creasingly implicated in the pathogenesis of DMD, although
it is not known if these abnormalities are associated with dys-
trophin deficiency, the pathophysiological sequelae caused by
dystrophin deficiency, or completely independent of dystro-
phin deficiency [6]. Indeed, the only obvious physical link
between dystrophin and the intracellular metabolic pathways
is via neuronal nitric oxide synthase (nNOS), whereby abla-
tion of dystrophin from the sarcolemma induces the secondary
loss of the dystrophin-associated proteins [7], including nNOS
[8, 9]. nNOS produces nitric oxide (NO), a key signaling
molecule in skeletal muscle that regulates various biological
processes, including blood flow, contraction, mass, satellite
cell activation, Ca2+ handling, and glucose uptake (GU), in
addition to mitochondrial metabolism, gene expression, and
reactive oxygen species (ROS) production [10]. In dystrophic
muscle, the dissociation of nNOS from the sarcolemma results
in reduced nNOS content [11–14], activity [9, 15, 16] and NO
production [17–19]. Importantly, this loss of nNOS has been
shown to contribute to the progression of the dystrophic con-
dition and to the deficits in metabolic function. For example,
nNOS is a positive allosteric regulator of phosphofructoki-
nase, the rate-limiting enzyme of the glycolytic pathway
[20], and therefore plays a critical role in regulating glucose
metabolism. Interestingly, DMD is not only associated with
impairments in glycolysis [20–22], but also in β-fatty acid
oxidation, the tricarboxylic acid cycle, and the electron trans-
port system (ETS) (for detailed reviewed see [6]).
Collectively, these metabolic impairments result in reduced
energy production [23], with reports of adenosine triphosphate
(ATP) content being 50% lower under resting conditions
[24, 25]. Given that nNOS localization and NO signaling are
known to be important for metabolic control, the loss of
nNOS, and NO bioavailability might be key to metabolic de-
regulation in dystrophic skeletal muscle. Therefore, increasing
NO availability has the potential to be of therapeutic benefit.
In an attempt to normalize NO production, several studies
have reintroduced nNOS into dystrophic skeletal muscle
which demonstrably reduces muscle damage and inflamma-
tion [26, 27]. As gene therapy for nNOS transfection is not yet
available in humans, other strategies to restore NO availability
have been investigated. Several studies have shown that sup-
plementation with NO donors, often combined with anti-
inflammatory drugs, results in reduced damage, necrosis and
inflammation, and improved muscle blood flow, function/
strength, and repair [28–35] in dystrophin-deficient skeletal
muscle. While these findings may suggest a positive effect
of increasing NO availability, it is difficult to control the de-
livery of NO to the skeletal muscle with pharmacological do-
nors and also to separate the effects of the NO donor from
those of the anti-inflammatory co-treatment. Another ap-
proach to increase NO availability has been to supplement
with the nNOS substrate, ˪-arginine [19]; however, the
potential for ˪-arginine to increase NO production is limited
by the lowered nNOS protein in dystrophic skeletal muscle.
An alternative method to increase NO availability, that is in-
dependent of nNOS activity, is supplementation with nitrate
(NITR). Specifically, dietary NITR can be reduced to nitrite
by commensal bacteria of the oral cavity and gastrointestinal
tract, with nitrite being subsequently reduced to NO via sev-
eral enzymatic pathways in the blood and tissues [36]. This
mechanism is complementary to NOS-derived NO production
and, importantly, represents a pathway that could be exploited
to increase NO availability in dystrophic muscle.
To date, no studies have investigated the effect of NITR
supplementation on metabolic function in dystrophic muscle;
however, recent studies suggest that NITR supplementation
has the potential to improve metabolic function in skeletal
muscle. For example, Larsen et al. [37] demonstrated that
NITR supplementation in healthy, young males led to in-
creased plasma NO concentration and, subsequently, down-
stream metabolic adaptations, including increased mitochon-
drial efficiency, reduced proton leak, and ultimately increased
ATP production capacity. Similar data have been derived in
rats during fatty-acid oxidation [38]. In addition, there is some
evidence that NITR supplementation can increase exercise
efficiency in humans [39–41] and exercise capacity in some
disease conditions such as peripheral arterial disease, where
NO production is reduced [42]. Most pertinently, increasing
NO bioavailability through administration of sodium nitrite
mitigates functional ischemia in patients with Becker muscu-
lar dystrophy [43], suggesting that expansion of the NITR–
nitrite–NO pool in DMD may also be beneficial. The results
from these studies prompted us to investigate whether increas-
ing NO availability via NITR supplementation, which has
been previously proven to increase plasma [37, 44] and skel-
etal muscle [38] NO levels and elicit beneficial mitochondrial
adaptations at the skeletal muscle level [37, 44], would im-
prove mitochondrial function and rectify energy homeostasis
dysregulation in dystrophic muscle. Therefore, we investigat-
ed whether an established dietary NITR supplementation reg-
imen [44] could improve GU, mitochondrial function, ROS
emission, and muscle architecture in healthy (control; CON)
and dystrophic (mdx) mouse models. We hypothesized that
NITR supplementation would 1) increase GU in the
contracting muscles from CON and mdx mice; 2) improve
mitochondrial function in mdxmice and; 3) improve the mus-
cle architecture of mdx mice.
Materials and Methods
Ethical approval
All experimental procedures were approved by the Victoria
University Animal Ethics Experimentation Committee and
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conformed to the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.
Animals and Supplementation
Three-week-old male C57Bl/10ScSn (normal wild-type
strain; CON) and C57Bl/10mdx (mdx) mice were purchased
from Animal Resources Centre (Western Australia, Australia)
and housed at the Western Centre for Health, Research and
Education (Sunshine Hospital, Victoria, Australia) on a
12:12 h light:dark cycle with ad libitum access to food and
water. Following a 1-week acclimatization period, mice were
randomly assigned into 4 groups: unsupplemented (CON
UNSUPP and mdx UNSUPP) and supplemented (CON
NITR andmdxNITR). Mice in the supplemented groups were
given 85 mg/l (1 mM) sodium NITR [44] ad libitum in drink-
ing water for 8 weeks and mice in the unsupplemented groups
were given drinking water without NITR. The dose of NITR is
comparable with doses studied in human experiments, is
achievable through a normal diet [45], and is proven to in-
crease the plasma NITR–nitrite–NO pool [37, 44].
Materials and Antibodies
All chemicals, unless stated otherwise, were purchased from
Sigma-Aldrich Chemicals (St. Louis, MO, USA). 2-Deoxy-
D-[1,2-3H]glucose and D-[14H]mannitol were purchased from
Perkin Elmer (Waltham, MA, USA). Dystrophin (ab15277),
nNOS (ab1376), nitrotyrosine (ab42789), and Total OXPHOS
(ab110413) primary antibodies were purchased from Abcam
(Cambridge, MA, USA). Secondary antibodies for immuno-
h i s t o ch em i s t r y we r e pu r cha s ed f r om Jack son
Immunoresearch Laboratories (West Grove, PA, USA) and
for Western blotting from Vector Laboratories (Burlingame,
CA, USA).
Muscle Dissection and Contraction Protocol
Mice were deeply anesthetized via intraperitoneal injection of
sodium pentobarbitone (60 mg/kg) and the white extensor
digitorum longus (EDL) and red soleus (SOL) muscle proxi-
mal and distal tendons in each hindlimb were tied with 4/0
surgical silk. Both EDL and SOL were surgically dissected
tendon-to-tendon and placed in individual muscle baths con-
taining Krebs basal buffer [118.5 mM NaCl, 24.7 mM
NaHCO3, 4.7 4 mM KCl, 1.18 mM MgSO4, 2.5 mM CaCl2,
8 mM mannitol, 2 mM Na pyruvate, 0.01% bovine serum
albumin (BSA); pH 7.4] bubbled with carbogen (95% O2,
5% CO2) at 30 °C. The proximal tendon was attached to a
force transducer and muscles were rested for 20 min to equil-
ibrate in the bath. Muscles were stimulated via square-wave
electrical pulses delivered by platinum electrodes flanking the
muscles, and subsequent recording of the force output were
obtained from a custom-built muscle analysis system
(Zultek Engineering, Victoria, Australia). Following de-
termination of optimal length (Lo) for each muscle via a
succession of isometric twitch contractions, the left EDL
and SOL were stimulated to contract for a total of 10 min
(pulse durations of 350 ms and 500 ms for EDL and SOL,
respectively, at a frequency of 60 Hz). This protocol
maintains muscle viability and maximizes GU [46]. The
right EDL and SOL were not stimulated in order to mea-
sure basal GU.
GU
Following 5 min of contraction, the Krebs basal buffer was
exchanged for Krebs buffer with 2-deoxy-D-[1,2-3H]glucose
(0.128 μCi/ml) and D-[14H]mannitol (0.083 μCi/ml) in both
resting and contracting muscles. At the end of the 10-min
contraction protocol, muscles were immediately submerged
in ice-cold Krebs basal buffer to stop further glucose uptake,
blotted on filter paper, and snap frozen in liquid nitrogen.
Whole muscles were weighed frozen, digested for 10 min at
95 °C in 135 μl 1 M NaOH, neutralized with 135 μl 1 M HCl,
and centrifuged for 5 min at 13,000 g. In total, 200 μl super-
natant was added to 4 ml inorganic scintillation fluid
(UltimaGold; Perkin Elmer) and radioactivity was measured
in aβ-scintillation counter (Tri-Carb 2810; Perkin Elmer). GU
was calculated as previously described [47].
Mitochondrial Respiration and Hydrogen Peroxide
Emission Measurements
Left and right gastrocnemius were excised from the anesthe-
tized mice, separated into red gastrocnemius (RG) and white
gastrocnemius (WG) portions and immediately placed into
ice-cold BIOPS [7.23 mM K2 ethylene glycol-bis(β-
aminoethyl ether)-N,N,N’,N’-tetracetic acid (EGTA),
2.77 mM CaK2EGTA, 5.77 mM Na2ATP, 6.56 mM MgCl2–
6H2O, 20 mM taurine, 15 mM phosphocreatine, 20 mM
imidizole, 0.5 mM dithiothreitol, 50 mM K+–MES; pH 7.1].
Muscle fibers were mechanically separated from a small por-
tion of muscle in ice-cold BIOPS to maximize fiber surface
area and transferred into ice-cold BIOPS supplemented with
saponin (50 μg/ml) for 30 min. Separated fibers were agitated
to permeabilize the sarcolemma and allow diffusion of subse-
quent assay substrates, and then washed 3 times via agitation
in ice-cold respiration buffer (110 mMK+–MES, 35mMKCl,
1 mMEGTA, 5 mMK2HPO4, 3 mMMgCl2–6H2O, 0.05 mM
pyruvate, 0.0 2 mM malate, 5 mg/ml BSA; pH 7.4). Fiber
bundles were then divided and weighed on a microbalance
(2–4 mg each) for subsequent respirometry analysis in
duplicate.
ETS respiration, OXPHOS, and hydrogen peroxide
(H2O2) emission were measured by the Oxygraph O2k high-
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resolution respirometer (Oroboros Instruments, Innsbruck,
Austria) via a substrate, uncoupler, inhibitor titration (SUIT) pro-
tocol at 37 °C in MIR05 respiration medium while stirring at
750 rpm, as previously described [48, 49], with minor modifica-
tions in order to assess H2O2 emission. Briefly, after fibers and
oxygen (O2) were added to the respiration chamber, the SUIT
protocol commenced with titrations of the complex I (CI) sub-
strates malate (2mM final concentration) and pyruvate (10mM),
followed by the complex II (CII) substrate succinate (10 mM) to
determine leak (state 4) respiration. Titrations of adenosine di-
phosphate (ADP; 0.25, 1, and 5 mM) assessed OXPHOS (state
3) capacity, addition of cytochrome c (10 μM) tested mitochon-
drial membrane integrity, and titrations of FCCP (0.025 μM)
determined uncoupled respiration. Complex-specific respiration
was inhibited by the addition of rotenone (1 μM) and antimycin
A (5 μM) to CI and complex III (CIII), respectively. Finally,
complex IV (CIV) capacity was measured during oxidation of
TMPD (0.5 mM) with ascorbate (2 mM). The O2 flux due to
auto-oxidation of these chemicalswas determined after inhibition
of CIVwith sodium azide (75mM) then subtracted from the raw
CIV O2 flux.
Mitochondrial H2O2 emission was simultaneously mea-
sured in the respiration chamber throughout the SUIT protocol
via optical sensors (O2k-Fluorescence LED-2 Module;
Oroboros, Innsbruck, Austria) as previously described
[50–52]. Superoxide (O2
–) produced during the SUIT protocol
was converted to H2O2 owing to the presence of a saturating
concentration of O2
– dismutase (2.5 U/ml), and the subse-
quent H2O2 generation was quantified via the reaction of
Amplex UltraRed (25 μM; Molecular Probes, Invitrogen,
Carlsbad, CA, USA) with horseradish peroxidase (2.5 U/ml)
at excitation/emission 565/600 nm wavelength. The H2O2 de-
tection chemicals were added to the chambers containing
MIR05 respiration medium at the beginning of the experi-
ment, prior to the addition of the muscle fibers.
Chamber O2 concentration was maintained between 300
and 450 nmol/ml. Mass-specific O2 flux and H2O2 emission
was determined from steady-state flux normalized to tissue
wet weight and adjusted for instrumental background and re-
sidual O2 consumption. Respiratory control ratios were calcu-
lated (complex specific O2 flux relative to maximal uncoupled
ETS respiration) to investigate intrinsic mitochondrial func-
tion independent of mitochondrial density.
Western Blot Analysis of Mitochondrial Respiratory
Chain Proteins
Frozen tissues were homogenized for 20 s in ice-cold WB
buffer (40 mMTris, pH 7.5; 1 mM ethylenediaminetetraacetic
acid; 5 mM EGTA; 0.5% Triton X-100; 25 mM β-
glycerophosphate; 25 mM NaF; 1 mM Na3VO4; 10 μg/ml
leupeptin; and 1 mM phenylmethylsulfonyl fluoride), and the
whole homogenate was used for further analysis. Sample
protein concentrations were determined with a DC protein
assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and
equivalent amounts of protein (15 μg) from each sample were
dissolved in Laemmli buffer, heated for 5 min at 37 °C, and
subjected to electrophoretic separation on sodium dodecyl
sulfate polyacrylamide gel electrophoresis gels. Following
electrophoretic separation, proteins were transferred to a
polyvinylidene fluoride membrane, blocked with 5% pow-
dered milk in Tris-buffered saline containing 0.1% Tween 20
(TBST) for 1 h followed by an overnight incubation at 4 °C
with primary antibody dissolved in TBST containing 1%
BSA. The Total OXPHOSAntibody Cocktail (1:1000), which
detects representative proteins from each of the 5 mitochon-
drial respiratory chain complexes, was obtained from Abcam.
This cocktail consisted of primary antibodies against the fol-
lowing proteins: NADH dehydrogenase (ubiquinone) 1 beta
sub-complex, 8 (CI), succinate dehydrogenase assembly fac-
tor 4 (CII), ubiquinol-cytochrome-C reductase complex core
protein 2 [complex III (CIII)], mitochondrially encoded cyto-
chrome C oxidase I (CIV), and mitochondrial ATP synthase
subunit alpha [complex V (CV)]. After overnight incubation,
the membranes were washed for 30 min in TBST and then
probed with a peroxidase-conjugated secondary antibody
(1:10,000, antimouse; Vector Laboratories) for 1 h at room
temperature. Following 30 min of washing in TBST, the blots
were developed with a DARQ CCD camera mounted to a
Fusion FX imaging system (Vilber Lourmat, Eberhardzell,
Germany) using ECL Prime reagent (Amersham,
Piscataway, NJ, USA). Once the images were captured, the
membranes were stained with Coomassie Blue to verify equal
loading of total protein in all lanes. Densitometric measure-
ments were carried out using Fusion CAPTAdvance software
(Vilber Lourmat).
Citrate synthase activity
Homogenized RG and WG samples were utilized to measure
citrate synthase (CS) activity as a marker of mitochondrial
density [53, 54]. Homogenized samples were added to reagent
cocktail (100 mM Tris Buffer, 1 mM DTNB, 3 mM acetyl
coenzymeA) and CS activity was measured spectrophotomet-
rically (412 nm at 25 °C) for 5 min following the addition of
10 mM oxaloacetate as described previously [23]. CS activity
was calculated using the extinction coefficient of 13.6 [55].
CS activity was normalized to whole muscle protein
concentration.
Histological Analysis
Following excision, the right tibilalis anterior (TA) was frozen
in liquid nitrogen-cooled isopentane and optimal cutting tem-
perature compound (Sakura Finetek, Alphen aan den Rijn, the
Netherlands). Embedded TAs were cryosectioned (10 μm) at
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–20 °C using a Leica (CM1950) cryostat and mounted onto
glass slides (Menzel-Glaser).
Dystrophin and nNOS immunolabeling
Slides were fixed using a Cytofix/Cytoperm Plus kit (BD
Biosciences, San Jose, CA, USA) for 5 min. After incubation
with blocking serum [0.1 M phosphate buffered saline (PBS),
0.1% triton, 10% fetal bovine serum] for 1 h at room temper-
ature, sections were labeled with primary antibodies: rabbit
antidystrophin (1:400) and goat anti-nNOS (1:200) overnight
at room temperature. After washing 3 times with a 0.1 M PBS
and 0.1% triton X solution, samples were incubated with sec-
ondary antibodies: donkey antirabbit Alexa 488 (1:200) and
donkey antigoat Alexa 594 (1:200) for 2 h at room tempera-
ture. Tissues were washed 3 times with a 0.1M PBS and 0.1%
triton X solution and mounted with fluorescent mounting me-
dium (DAKO, North Sydney, Australia). Confocal microsco-
py was performed on an Eclipse Ti confocal laser scanning
system (Nikon, Tokyo, Japan). Fluorophores were visualized
using a 488-nm excitation filter for Alexa 488 or fluorescein
isothiocyanate and a 559-nm excitation filter for Alexa 594 or
Rhodamine Red. Z-series images were acquired at a nominal
thickness of 0.5 μm (512 × 512 pixels). The density of dys-
trophin and nNOS immunoreactivity in TA sections was mea-
sured from 8 randomly captured images (total area size
2 mm2) per animal at 20× magnification. All images were
captured under identical acquisition exposure time conditions
and calibrated to standardized minimum baseline fluores-
cence. Images were converted from red, green, and blue to
grayscale 8-bit then to binary; changes in fluorescence from
the baseline were measured using Image J software (NIH,
Bethesda, MD, USA). The area of immunoreactivity was then
expressed as a percentage of the total area examined.
Quantitative analyses were conducted blindly.
Nitrotyrosine, CD45, and IgG immunolabeling
Slides were fixed with 4% formaldehyde for 30 min at room
temperature. After incubation with blocking serum (0.1 M
PBS, 0.1% triton, 10% donkey serum) for 1 h at room tem-
perature, sections were then labeled with primary anti-S-
nitrotyrosine (rabbit; 1:200; Millipore, Billerica, MA, USA),
anti-CD45 (pan-leukocyte marker; rat; 1:200), and anti-IgG
isotype control (hamster; 1:200) primary antibodies overnight
at room temperature. After washing 3 times with a 0.1 M PBS
and 0.1% triton X solution, samples were incubated with the
appropriate secondary antibody [anti-rabbit Alexa Fluor 647,
1:100 (Abacus ALS, UK); anti-rat Alexa Fluor 488 (Jackson
Immunoresearch Laboratories); anti-hamster Alexa Fluor 594
(Jackson Immunoresearch Laboratories)] for 2 h at room tem-
perature. A pan-nuclei marker 4',6-diamidino-2-phenylindole
(DAPI) was added to the tissue sections and incubated for
2 min at room temperature, tissues were washed 3 times with
a 0.1 M PBS and 0.1% triton X solution and mounted with an
anti-fade fluorescent mounting medium. Excitation wave-
lengths were set to 640 nm for Alexa 647, 406 nm for Alexa
405, 408.8 nm for Alexa Fluor 488, and 561.8 nm for Alexa
Fluor 594. The confocal microscope was calibrated to stan-
dardize the minimum baseline fluorescence for imaging
nitrotyrosine, CD45, and IgG immunoreactivity in the TA
cross sections. At time of analysis all files were converted to
thresholded 8-bit binary images using ImageJ software from 8
randomly captured images per animal. Images were analyzed
through the Banalyze particles^ function, recording the counts
(to determine the number of DAPI-positive nuclei) and rela-
tive nitrotyrosine expression recorded as percentage area frac-
tion in arbitrary units. CD45+ and IgG immunoreactivity was
recorded in arbitrary units. Green pseudocolor images of
nitrotyrosine (Alexa Fluor 647; magenta) were generated
using ImageJ software for publication only.
Hematoxylin and eosin staining
Slides were air-dried and stained using a hematoxylin and
eosin staining protocol, including a 30-s incubation in hema-
toxylin and a 1-min and 45-s incubation in eosin. Slides were
imaged using a Zeiss Axio Imager Z2 microscope at 20×
magnification. Fiber size, damaged area (areas of myofibril
demise and inflammatory cell infiltration [56]), and fibers
with centralized nuclei were determined using ImageJ
software.
Statistics
Results are presented as mean ± SEM. For all data, except for
GU, a 2-way analysis of variance was utilized to detect between
strain/genotype (CON vs. mdx) and supplementation (UNSUPP
vs. NITR) differences. For GU data, a 3-way analysis of variance
was performed for each of EDL and SOL to detect between
strain, supplementation, and GU type (basal vs contraction).
When a main effect or an interaction was detected, unpaired t
tests were used to determine differences between individual
groups using SPSS (version 21; IBM, Armonk, NY, USA). An
α value of 0.05 was considered significant.
Results
Effect of NITR Supplementation on Body Weight, Food
and Water Consumption, and Muscle Weights
Throughout the 8-week supplementation period, greater
weight gains were observed in themdx groups compared with
CON (p < 0.0001; Fig. 1a), with NITR having no effect inmdx
mice (p > 0.05). NITR did, however, stimulate weight gain in
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CON (p < 0.05). No significant difference in food or water
consumption was observed between any group over the sup-
plementation period (Fig. 1b, c, respectively; p > 0.05) except
at week 2, where food consumption was greater in CON
UNSUPP than in all groups (p < 0.05; Fig. 1b). Overall,
individual hindlimb muscle weights were greater in the mdx
than in the CON strain (p < 0.0001; Tables 1 and 2) with NITR
having no effect (p > 0.05).
Immunolabeling of Dystrophin and nNOS
To confirm the deficiency of both dystrophin and nNOS in
mdx skeletal muscle, the presence of dystrophin and nNOS
protein was determined in the TA (Fig. S1). Indeed, dystro-
phin was only evident in CON TA (Fig. S1A, C) and was
absent from mdx TA except for a few spontaneously revertant
fibers (p < 0.0001). Similarly, nNOSwas only evident in CON
TA (Fig. S1AI, CI), and was completely absent from
dystrophin-deficient mdx fibers (p < 0.0001). Co-localization
of dystrophin and nNOS was only observed in CON
(Fig. S1AII, CII), and NITR had no effect on either dystrophin
or nNOS expression (p > 0.05).
Effect of NITR Supplementation on GU
NO has been proposed to play a role in contraction-stimulated
GU and, as such, we first investigated the effect of NITR
supplementation on GU in CON and mdx muscles. This is
the first instance of contraction-induced GU being measured
in themdxmouse and we demonstrated no difference in basal-
or contraction-induced GU between CON and mdx UNSUPP
EDL (p > 0.05; Fig. 2a). As expected, contraction induced an
increase in GU in the EDLs of CON UNSUPP (55%), CON
NITR (61%), mdx UNSUPP (35%), and mdx NITR (51%)
compared with basal conditions (p < 0.05; Fig. 2a). NITR sup-
plementation significantly increased contraction-induced GU
in CON EDL muscles (p < 0.05; Fig. 2a); however, in con-
trast, NITR reduced both basal- and contraction-induced GU
in mdx muscles (p < 0.05; Fig. 2a). Contrary to the EDL, con-
traction did not stimulate further GU beyond that observed in
basal conditions for any group in the SOL (all < 20%,
p > 0.05; Fig. 2b). While NITR had no effect on basal or
contraction-induced GU in CON SOL muscles (p > 0.05;
Fig. 2b), NITR further reduced both basal and contraction-
induced GU inmdx SOL muscles (p < 0.05). Combined, these
data suggest that NITR supplementation has a negative effect
on GU in bothmdx EDL and SOL, which may lead to impair-
ments in downstream glycolysis and oxidative metabolism.
Effect of NITR Supplementation on Mitochondrial
Function
Respirometry
Next, we examined the effect of NITR on parameters of mi-
tochondrial function. First, we measured state 4 leak respira-
tion, which, in the absence of ADP, indicates the contribution
of proton leak to respiration. In the presence of pyruvate and
Fig. 1 Body weight and average food and water consumption of
unsupplemented (UNSUPP) and nitrate (NITR)-supplemented mice
over the supplementation period. (a) Changes in body weight are
shown as a percentage of presupplementation weight. Overall, mdx
mice gained more weight over the 8-week supplementation period than
control mice (CON; p < 0.0001). NITR had no effect onmdxweight gain
but did increase weight gain in CON compared with CON UNSUPP
(p < 0.05). Over the 8-week supplementation period, (b) food and (c)
water consumption did not differ between unsupplemented and
supplemented animals (p > 0.05) except for food consumption during
week 2, where CON UNSUPP consumed more than all groups
(p < 0.05). CON UNSUPP n = 16; CON NITR n = 17; mdx UNSUPP
n = 14; mdx NITR n = 18
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malate (CI), state 4 leak respiration was significantly lower in
mdx WG (p < 0.05; Fig. 3a) and RG (p < 0.01; Fig. 3c) mus-
cles compared with their respective controls. In the presence
of pyruvate, malate, and succinate (CI + II), state 4 leak respi-
ration was significantly higher than CI respiration across all
groups, in both WG and RG muscles (p < 0.0001; Fig. 3a, c,
respectively). NITR supplementation had no effect on either
CI or CI + II state 4 leak respiration in CON or mdx muscles
(Fig. 3a, c).
Next, the effect of NITR on coupled OXPHOS capacity
was examined in WG and RG muscles by assessing maximal
ADP-stimulated state 3 respiration in the presence of excess
malate, pyruvate, and succinate (CI + II substrates). As shown
in Fig. 3, state 3 respiration was significantly depressed inmdx
WG by ~15% (p < 0.05; Fig. 3a) and in mdx RG by 25%
(p < 0.001; Fig. 3c) compared with CON. NITR supplemen-
tation, however, had no effect on state 3 respiration in either
muscle (Fig. 3a, c).
Maximal ETS capacity was then assessed by the addition
of the uncoupling agent FCCP, which dissipates the mitochon-
drial membrane potential (ΔΨ). This parameter gives an indi-
cation of the maximal respiration in the uncoupled state.
FCCP-induced maximal uncoupled respiration was signifi-
cantly lower in mdx WG (p < 0.05; Fig. 3a) and RG
(p < 0.001; Fig. 3c) compared with their respective controls;
however, there was no effect of NITR on this parameter.
Next, we measured the activity of CIV (cytochrome C ox-
idase), the terminal oxidase of the ETS and the site of O2
reduction to water. As shown in Fig. 3, CIV activity was not
different between UNSUPP CON and mdx WG muscles
(Fig. 3a); however, in the RG muscles, CIV activity was
Fig. 2 Glucose uptake (GU) in isolated extensor digitorum longus (EDL)
and soleus (SOL) from unsupplemented (UNSUPP) and nitrate (NITR)
supplemented CON and mdxmice. (a) In all groups, contraction-induced
GU significantly increased compared with basal conditions (p < 0.05).
NITR increased contraction-induced GU in CON EDL (p < 0.05) but, in
contrast, reduced both basal- and contraction-induced GU in mdx EDL
(p < 0.05). (b) For the SOL, both basal- and contraction-induced GUwere
comparable (p > 0.05). NITR reduced basal GU in mdx SOL (p < 0.05)
but had no effect in CON SOL. CON UNSUPP n = 9–13; CON NITR
n = 11; mdx UNSUPP n = 11; mdx NITR n = 10–12
Table 1 Weights of extensor
digitorum longus (EDL) and
soleus (SOL) used in glucose
uptake experimentation*
Left EDL (mg) Right EDL (mg) Left SOL (mg) Right SOL (mg)
CON UNSUPP (n = 14) 12.3 ± 0.8 12.4 ± 1.2 9.0 ± 0.9 9.8 ± 0.9
CON NITR (n = 16) 11.3 ± 0.3 12.6 ± 0.8 10.3 ± 0.5 10.3 ± 0.6
mdx UNSUPP (n = 12) 14.8 ± 0.8† 15.5 ± 1.4† 13.5 ± 1.3† 14.9 ± 1.4†
mdx NITR (n = 13) 14.7 ± 0.9† 16.0 ± 0.8† 13.7 ± 0.8† 13.3 ± 0.6†
*Irrespective of supplementation, both EDL and SOL weights were significantly higher in mdx mice compared
with control (CON) mice. There was no effect of nitrate (NITR)
† Significant difference from CON mice (p < 0.0001)
Table 2 Weights of the left gastrocnemius used in mitochondrial
respiration experimentation, determination of citrate synthase activity
and Western blotting of mitochondrial complexes and the right tibilalis
anterior (TA) used for immunohistochemistry*
Gastrocnemius (mg) TA (mg)
CON UNSUPP (n = 13) 145.18 ± 4.4 46.9 ± 1.7
CON NITR (n = 16) 145.2 ± 3.3 46.5 ± 1.5
mdx UNSUPP (n = 12) 169.9 ± 4.2† 68.9 ± 2.1†
mdx NITR (n = 13) 170.2 ± 4.5† 66.9 ± 4.3†
*Irrespective of supplementation, gastrocnemius was significantly higher
in mdx mice compared with control (CON) mice. There was no effect of
nitrate (NITR). Similarly, TAwas significantly higher in mdx mice com-
pared with CON mice with no effect of NITR observed in either strain
† Significant difference from CON mice (p < 0.0001)
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significantly lower in mdx UNSUPP compared with CON
UNSUPP (p < 0.01; Fig. 3c). NITR induced a significant in-
crease in CIVactivity in CONWGmuscles (p < 0.01; Fig. 3a)
but reduced CIV activity in both CON and mdx RG muscles
(p < 0.01; Fig. 3c).
Finally, the respiratory control ratio (RCR; state 3 respiration
divided by state 4 respiration) was calculated. The RCR is an
indicator of the extent to which O2 consumption is coupled to
ATP production and therefore mitochondrial efficiency, with a
higher RCR indicating better coupling. No difference in RCR
was observed between CON and mdx WG (p > 0.05; see
Fig. 5b). In mdx RG respiring on CI + II, the RCR was signif-
icantly lower compared to CON (p < 0.0001) and NITR de-
creased the RCR further (p < 0.01; Fig. 3d). This highlights that
in oxidative red muscle at least, mdx mitochondria are more
uncoupled and that this uncoupling is exacerbated by NITR.
Fig. 3 Mitochondrial function in intact, permeabilized muscle fibers
from the white (WG) and red portion of gastrocnemius (RG) from
unsupplemented (UNSUPP) and nitrate (NITR)-supplemented control
(CON) and mdx mice. (a) State 4 leak respiration is significantly
reduced in mdx compared with CON WG, irrespective of substrate
combination (p < 0.05). (a) Adenosine diphosphate-stimulated state 3
respiration is significantly reduced in mdx compared with CON WG
(p < 0.05) with NITR having no effect. (a) FCCP-stimulated uncoupled
respiration is significantly reduced in mdx WG compared with CON
(p < 0.05) with no difference in complex IV (CIV) activity detected
between CON and mdx WG (p > 0.05). (b) The respiratory control ratio
(RCR), an indicator of the coupling of O2 consumption and adenosine
triphosphate production at the electron transport system, was comparable
between CON and mdx WG, although a trend for mdx to be lower was
detected (p = 0.083). When respiring on complex I (CI) + complex II
(CII) substrates, the RCR was significantly lower across all groups
(p < 0.0001). (c) State 4 leak respiration was significantly reduced in
mdx compared with CON RG, irrespective of substrate combination
(p < 0.01). ADP-stimulated state 3 respiration was significantly reduced
in mdx compared with CON RG (p < 0.001) with NITR having no effect
on phosphorylating respiration. FCCP-stimulated uncoupled respiration
was significantly reduced in mdx compared with CON (p < 0.001). CIV
activity was significantly reduced in mdx UNSUPP compared with CON
UNSUPP (p < 0.01) with NITR inducing a significant decrease in both
CON and mdx (p < 0.01). (d) The RCR in mdx RG during CI + II-
stimulated respiration was lower compared with CON (p < 0.0001) with
NITR decreasing the RCR in mdx during CI + II-stimulated respiration
(p < 0.001, respectively). CON UNSUPP n = 12–13; CON NITR n = 12–
13; mdx UNSUPP n = 10–11; mdx NITR n = 11–12
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Electron transport chain complex expression
To determine whether the genotypic differences and NITR
supplementation-induced changes in respiration parameters
were associated with differences in mitochondrial ETS com-
plex densities, the abundance of representative proteins from
each of the 5 ETS complexes were measured using semiquan-
titative Western blotting (Figs. 4 and 5). In WG muscles,
despite state 3, state 4, and maximal uncoupled respiration
being lower in mdx muscles (Fig. 3a), the relative abundance
of representative proteins from complexes I to V were not
lower. In fact, to the contrary, proteins from CII, CIII, CIV,
and CV were significantly elevated in mdx UNSUPP WG
muscles compared with CON UNSUPP muscles (Fig. 4).
Interestingly, the NITR-induced increase in CIV respiratory
activity (Fig. 3a) was not associated with a significant increase
Fig. 4 Mitochondrial respiratory
chain complex proteins, and
citrate synthase (CS) activity,
from the white portion of
gastrocnemius (WG) from
unsupplemented (UNSUPP) and
nitrate (NITR)-supplemented
control (CON) and mdx mice. In
mdxUNSUPPWG, expression of
(b) complex II (CII; p < 0.05), (c)
complex III (CIII; p < 0.01), (d)
complex IV (CIV; p < 0.05), and
(E) complex V (CV; p < 0.01)
were greater compared with CON
UNSUPP. NITR induced an
increase in (a) CI (p < 0.01), (b)
CII (p < 0.01), (c) CIII (p < 0.05),
and (e) CV (p < 0.05) subunits in
CONWG but not in mdxWG. (f)
NITR also increased CS activity
in both CON and mdx WG
(p < 0.05) with a trend for CS
activity to be higher in mdx
UNSUPP compared with CON
(p = 0.07). (g, h) Representative
Western blots of proteins from
each of the 5 mitochondrial
respiratory complexes with
Coomassie blue stains of the
respective Western blots to
demonstrate equal loading of the
total protein. n = 8 per group
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in the abundance of the CIV protein (Fig. 4d). NITR supple-
mentation did, however, lead to an increase in representative
proteins in WGmuscles for CI, CII, CIII, and CV in CON but
not mdx muscles (Fig. 4).
Unlike the WG muscles, the lower state 3, state 4,
uncoupled respiration, and CIV activity found in RG mdx
muscles (Fig. 3c) was accompanied by a reduction in repre-
sentative proteins for CI, CII, CIV, and CV compared with
CON; however, NITR supplementation had no effect on any
of these proteins in either CON or mdx RG muscles (Fig. 5).
CS activity
Finally, we measured CS activity in WG and RG muscles as a
co-marker of mitochondrial content alongside mitochondrial
ETC proteins [53] (Figs. 4f and 5f, respectively). As shown in
Fig. 5 Mitochondrial respiratory
chain complex proteins, and
citrate synthase (CS) activity from
the red portion of gastrocnemius
(RG) from unsupplemented
(UNSUPP) and nitrate (NITR)
supplemented control (CON) and
mdx mice. Overall, expression of
(a) complex I (CI), (c) complex III
(CIII), (d) complex IV (CIV), and
(e) complex V (CV) subunits
were decreased in mdx RG
compared with CON (p < 0.05).
(f) NITR increased CS activity in
mdx RG but not in CON
(p < 0.05). (g, h) Representative
Western blots of proteins from
each of the 5 mitochondrial
respiratory complexes with
Coomassie blue stains of the
respective western blots to
demonstrate equal loading of the
total protein. n = 8 per group
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Fig. 4f, there was a trend for CS activity to be higher in mdx
UNSUPP compared with CON UNSUPP WG muscles.
Moreover, NITR increased CS activity in both CON and
mdxWGmuscles. In the RG muscles there was no difference
in CS activity between UNSUPP CON and mdx mice; how-
ever, NITR increased CS activity in RG muscles from mdx
mice. Overall, NITR did not improve the capacity to phos-
phorylate ATP or maximal respiratory capacity in dystrophic
muscle despite increasing CS activity, suggesting that NITR
may have an alternative effect on mitochondrial function such
as ROS generation.
Effect of NITR Supplementation on ROS Production
in RG and WG
The effect of NITR supplementation on the production of
the mitochondrial ROS superoxide (O2
–) was measured
in intact and permeabilized fibers from WG and RG si-
multaneously with respiration. In the presence of excess
O2
– dismutase, O2
– is converted to hydrogen peroxide
(H2O2), which reacts with Amplex Red to produce the
red fluorescent product, resorufin. During state 3 respira-
tion, no differences in H2O2 emission were detected be-
tween CON and mdx UNSUPP WG (p > 0.05; Fig. 6a)
with NITR having no effect in either strain (p > 0.05;
Fig. 6a). NITR did, however, induce a decrease in
H2O2 emission during state 4 leak respiration in CON
WG muscle fibers respiring on CI substrates (p < 0.05;
Fig. 6a). When respiring on CI + CII substrates, there
was significantly greater H2O2 emission in all groups
during state 4 leak respiration compared with CI sub-
strates only in WG fibers (p < 0.0001; Fig. 6a).
Importantly, NITR significantly decreased H2O2 emission
in both CON and mdx WG muscles respiring during state
4 while on CI + II substrates (p < 0.05; Fig. 6a). There
was no difference in H2O2 emission in WG between
any groups during FCCP-stimulated maximal uncoupled
respiration (p > 0.05; Fig. 6a).
In mdx RG fibers, there was significantly less H2O2 emis-
sion during state 3 respiration (p < 0.05; Fig. 6b) compared
with CON fibers; however, there was no effect of NITR on
this parameter (p > 0.05). Similar to WG fibers, H2O2 emis-
sion was higher when respiring on CI + CII substrates com-
pared with CI substrates across all groups during state 4 leak
respiration (p < 0.0001); however, NITR only reduced H2O2
emission in mdx fibers (p < 0 .001; Fig. 6b). NITR also re-
duced H2O2 emission in mdx RG fibers during FCCP
uncoupled respiration (p < 0.05; Fig. 6b). While our data sug-
gest that NITR reduces mitochondrial ROS production in dys-
trophic muscle, it is possible that increased NO bioavailability
may sequester O2
– from the O2
– dismutase reaction to increase
reactive nitrogen species (RNS).
Effect of NITR Supplementation on Peroxynitrite
Production, CD45+ Infiltration and IgG Immunolabeling
NO is known to react rapidly with O2
– resulting in the pro-
duction of the highly RNS, peroxynitrite (ONOO–), and given
that elevated ROS is present in mdx muscle [57], we investi-
gated whether ONOO– production could account for the
Fig. 6 H2O2 emission in intact fibers from the (a) white (WG) and (b)
red (RG) portions of gastrocnemius from unsupplemented (UNSUPP)
and nitrate (NITR)-supplemented control (CON) and mdx mice. (a) In
WG, NITR induced a decreased H2O2 emission during state 4 leak
respiration in CON during complex I (CI)-stimulated respiration and in
both CON and mdx during CI + complex II (CII)-stimulated respiration
(p < 0.05). (a) In WG, no significant difference was detected in H2O2
emission during adenosine diphosphate (ADP)-stimulated state 3
respiration. There was no significant difference in H2O2 emission
during FCCP-stimulated uncoupled respiration in WG. (b) In RG,
NITR induced a decrease in H2O2 emission during state 4 leak
respiration in mdx muscle during CI + CII-stimulated respiration
(p < 0.001). (b) In mdx RG, H2O2 emission during ADP-stimulated
state 3 respiration was significantly less compared with CON WG
(p < 0.05) with NITR having no effect (p > 0.05). (b) While there were
no differences in H2O2 emission during FCCP respiration between CON
UNSUPP and mdx UNSUPP RG (p > 0.05), NITR reduced H2O2
emission in mdx RG compared with mdx UNSUPP (p < 0.05). CON
UNSUPP n = 12–13; CON NITR n = 12–13; mdx UNSUPP n = 10–11;
mdx NITR n = 11–12
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reduced H2O2 emission observed in our study. Increased
ONOO– can result in increased protein nitration of tyrosine
residues, potentially leading to altered protein function.
Therefore, as an indirect marker of oxidative/nitrosative stress,
we measured the effect of NITR on levels of nitrotyrosine via
immunohistochemical staining of TA muscles. Mdx muscles
had significantly higher nitrotyrosine staining compared with
CON muscles (p < 0.0001) and NITR increased nitrotyrosine
staining in both CON (p < 0.05) and mdx (p < 0.0001) TA
(Fig. 7a and Fig. S2). Importantly, NITR induced a dramati-
cally greater increase in nitrotyrosine production in mdx mus-
cles (2775% increase vs 82% increase in CON). Additionally,
NITR further increased the presence of DAPI-stained nuclei in
NITR supplemented mdx TA (p < 0.0001; Fig. 7b and
Fig. S2). To assess if the increased nitrotyrosine staining was
associated with increased inflammation, we measured CD45+
immune cell infiltration and IgG via immunolabeling. In mdx
TA, both CD45+ and IgG+ area was elevated compared with
CONmuscles (p < 0.001 and p < 0.01, respectively; Fig. 7c, d,
respectively and Fig. S3). In contrast to nitrotyrosine staining,
NITR had no effect on the CD45+ and IgG+ area in either
strain (p > 0.05).
Effect of NITR Supplementation on Muscle Architecture
Finally, we assessed the effect of NITR on muscle fiber histo-
pathology. As expected, intact mdx muscle fibers were signif-
icantly larger than fibers fromCONmuscles (Fig. 8a, c) which
is representative of pseudohypertrophy, a hallmark histopath-
ological feature of dystrophin-deficient muscle. Interestingly,
there was a strong trend for NITR supplementation to increase
the number of fibers between 6000 and 7499 μm2 (p = 0.068;
Fig. 8a) and increase total mean fiber size (p = 0.093; Fig. 8c).
The area of damage, as indicated by areas of inflammato-
ry cell/nuclei infiltration, was significantly higher in mdx
(p < 0.01; Fig. 8d) compared with CON TA sections, and
NITR significantly increased the damage area in mdx
muscle (p < 0.01). Centronucleated fibers, a marker of
muscle cell regeneration, were significantly higher in
mdx muscle (p < 0.0001; Fig. 8e) with NITR further in-
creasing regeneration area in mdx sections (p < 0.01).
These results show that NITR supplementation not only
enhances muscle damage, but also regeneration in mdx
TA but not in CON, which seems reflective of the in-
creased ONOO– production.
Fig. 7 Immunohistological analysis of tibilalis anterior (TA) from
unsupplemented (UNSUPP) and nitrate (NITR)-supplemented control
(CON) and mdx mice. (a) Nitrotyrosine expression was higher in mdx
TA compared with CON (p < 0.0001) with NITR supplementation
elevating nitrotyrosine expression in both CON (p < 0.05) and mdx
(p < 0.0001). (b) Nuclei content was higher in mdx TA compared with
CON (p < 0.0001) with NITR further increasing nuclei content inmdx TA
(p < 0.0001). (c) CD45 infiltration and (d) IgG staining was elevated in
mdx TA compared with CON (p < 0.001 and p < 0.01, respectively) and
NITR supplementation had no effect in either CON ormdx TA (p > 0.05).
Scale bars = 100 μm. CON UNSUPP n = 3–4; CON NITR n = 3–4; mdx
UNSUPP n = 3–4; mdx NITR n = 3–4
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Discussion
This is the first study to date to investigate NITR supplemen-
tation as a potential therapy for DMD, and we show that the
metabolic perturbations in dystrophin-deficient skeletal mus-
cle could not be overcome by enhancing nNOS-independent
NO production. Instead, our data suggest that chronically in-
creasing NO bioavailability without restoring nNOS protein
expression and its regulatory role on metabolism, in fact, pro-
motes pathological muscle damage, potentially via a ONOO–-
dependent mechanism.
In the first instance, we investigated if impaired macronu-
trient uptake may be a contributing factor to the mitochondrial
dysfunction in dystrophic muscle, as compromised transport
of substrates across the sarcolemma could be a consequence of
the loss of dystrophin and nNOS from the membrane.
Specifically, we have investigated GU, as it is well established
that GU during rest and contraction is regulated by NO [46].
The secondary loss of dystrophin-associated nNOS was con-
firmed inmdx TAvia immunolabeling. Concurrently, we have
demonstrated that both basal- and contraction-induced GU in
both mdx UNSUPP EDL and SOL is comparable with CON.
We have demonstrated in our study that NITR increases
contraction-induced GU in CON EDL but has no effect in
CON SOL. Indeed, we have shown previously that there are
greater effects of NOS inhibition on EDL than SOL [46],
likely because of a greater comparative nNOS expression in
fast-twitch versus slow-twitch muscles [46, 58] and the higher
antioxidant enzymes in slow-twitch muscles which may buff-
er the effects of NO [59]. In both CON EDL and SOL mus-
cles, however, NITR did not affect basal GU rate. This could
infer that the NITR dosage administered in our study is suffi-
cient to modulate non-cyclic guanosine monophosphate
(cGMP)-dependent contraction-induced glucose transporter
Fig. 8 Histologic analysis of tibilalis anterior (TA) from unsupplemented
(UNSUPP) and nitrate (NITR)-supplemented control (CON) and mdx
mice. (a) The frequency histogram indicates an increase in fiber size of
mdx TAwith fibers more frequent from 6000 to 12,000 μm (p < 0.0001).
NITR had no effect on the distribution of CON or mdx fibers, but there
was a trend for an increased number of fibers around 6000 μm
(p = 0.068). (c) Mean fiber size was significantly greater in mdx TA
(p < 0.01) with a trend for NITR to increase fiber size in mdx TA
(p = 0.093). (d) Damaged area and (e) percent centronucleated fibers
was significantly higher in mdx TA (p < 0.01 and p < 0.0001,
respectively) with NITR stimulating further damage and regeneration
(p < 0.01). CON UNSUPP n = 11; CON NITR n = 12; mdx UNSUPP
n = 11; mdx NITR n = 10
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4-mediated GU [60] but perhaps not cGMP-dependent glu-
cose transporter 1 basal [61] events. A notable limitation of
our study is that we did not quantify cGMP levels in EDL and
SOL muscles. However, in light of a recent study which dem-
onstrated that even low-dose (0.35 mM) NITR therapy for
~2 weeks (in comparison with the 1 mM NITR dosage for
8 weeks administered in our study) was sufficient to induce
~3-fold increases in cGMP levels in rat skeletal muscle, this
seems unlikely. Rather, basal GU is likely regulated in the first
instance by glucose utilization, thus increasing NO signaling
without the normal simultaneous increase in muscle work
(and thus glucose utilization) results in an unchanged basal
GU. Unexpectedly and in contrast to CON EDL, NITR re-
duced basal GU in mdx EDL and SOL. Taken with the fact
that NITR stimulated contraction-induced GU in CON but
further depressed it in mdx muscle, our data suggest that
NITR-derived NO is being diverted away from its
biomodulatory effects on GU. Presumably, this is because in
mdxmuscle, in which O2
– production is notoriously increased
[57], NITR-generated NO is being sequestered into ONOO–
production instead of cGMP activation, thus reducing the pro-
portional NO available to GU signaling despite an increased
NITR–nitrite–NO pool.
We have assessed various indices of mitochondrial respira-
tory function in permeabilized RG and WG gastrocnemius
fiber bundles. Permeabilization of intact muscle bundles and
delivery of optimal substrate concentrations allows for the
measurement of the mitochondrial capacity independent of
substrate delivery capacity. Indeed, even in this optimized
environment, we demonstrate a reduced capacity (up to 25%
of CON) to phosphorylate ADP in both WG and RG from the
mdx mouse. This is consistent with others [62, 63] who have
reported similar depressions in ADP-stimulated phosphorylat-
ing respiration in mdx skeletal muscle fibers. NITR did not
improve phosphorylating or maximal uncoupled respiration in
either CON or mdx skeletal muscle but did decrease CIV
activity in both CON and mdx RG. CIV inhibition is an
established effect of reversible competitive binding of NO to
heme-copper sites in lieu of O2 on CIV, in addition to CI and
CIII [64–66]. Despite the inhibitory effect of NITR on CIV
activity and therefore ETS respiratory capacity, the lack of
effect on phosphorylating and maximal uncoupled respiration
was unexpected, as NITR has been previously shown to im-
prove various mitochondrial properties through stimulation of
mitochondrial biogenesis and improved coupling of O2 con-
sumption to ATP production [37]. As NO is a highly reactive
molecule that, to exert its biological role, must be produced in
close proximity to its effector targets, the exogenous NO
source afforded by NITR supplementation in our study may
not be penetrating the muscle fibers sufficiently, or in suffi-
cient concentration, to modulate mitochondrial function. This
is particularly true of the mitochondrial function governed by
nuclear gene regulation such as mitochondrial biogenesis and
uncoupling. Aquilano et al. [67], for instance, have demon-
strated that the loss of nNOS-generated NO production nearby
the nucleus is a causative factor of the impairment of mito-
chondrial biogenesis in skeletal muscle. Thus, while we have
evidence of NITR-derived NO penetrating the mitochondria
to induce regulatory adaptations such as inhibition of CIV
activity, overall respiratory capacity which is dictated predom-
inantly by mitochondrial density and coupling is seemingly
unaffected, even in CONmice. This is likely due to the chron-
ic supplementation period and particular dosage employed in
our study. For example, similar to our study, Hezel et al. [68]
did not observe any changes in mitochondrial parameters fol-
lowing 17 months of NITR supplementation in healthy mice.
In contrast, others have shown beneficial mitochondrial mod-
ulation following much shorter supplementation periods
[37, 69]. Ashmore et al. [38] have recently demonstrated that
NITR dosage is also important to the control of the nuclear
signaling of mitochondrial biogenesis in which low-
(0.35 mM), medium- (0.7 mM), and high- (1.4 mM) dose
NITR therapy (for 15–18 days) in rats had differential effects
on peroxisome proliferator-activated receptorα/β/δ signaling,
PGC-1α expression, CS activity, and mitochondrial fatty acid
oxidation. These data highlight that the promotion of mito-
chondrial biogenesis might be an acute, dose-specific re-
sponse to shorter-term increases in skeletal muscle NO signal-
ing, which may switch off or become desensitized in response
to more chronic, prolonged increases in NO production.
The reduced capacity for mdx skeletal muscle to phosphor-
ylate ADP and to ramp up respiration during times of meta-
bolic stress may be reflective of uncoupled respiration. In our
study, state 4 respiration was significantly less in bothWG and
RG ofmdxmice and the RCR was lower inmdx RG respiring
on CI + II substrates highlighting that respiratory control is
compromised in the muscle that is most dependent upon mi-
tochondrial oxidative ATP production (i.e. red oxidative mus-
cle). When considered in context of a depressed state 3 and 4
respiration, tighter respiratory control would be required to
maintain the ΔΨ and drive for ATP synthesis, especially giv-
en the heightened energy requirements of dystrophic muscle.
Indeed, our observations of a depolarizedΔΨ in isolated mdx
mitochondria (C.A. Timpani, A. Hayes and E. Rybalka, un-
published observations) indicate insufficient coupling to
maintain the drive for ATP synthesis in red muscle at least.
Intriguingly, NITR decreased the RCR only in mdx muscles,
indicative of mitochondrial uncoupling. Uncoupling may be a
beneficial adaptation to ETS dysfunction, to prevent potential
hyperpolarization of the ΔΨ which is an initiator of
mitochondria-mediated apoptosis [70]. Certainly, the role of
NITR-derived NO in the regulation of mitochondrial coupling
efficiency is unclear as some studies have demonstrated an
enhanced coupling efficiency of human skeletal muscle [37],
while others have shown a reduced coupling efficiency of
rodent skeletal muscle [38]. Despite the obvious species
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differences between these studies, these data highlight that
NITR-derived NO has a modulatory role on the expression
of uncoupling protein 3 (through increased peroxisome
proliferator-activated receptor-α activation [38]) and adenine
nucleotide translocase expression, and seemingly regulates
the leakiness of several respiratory complexes—all of which
contribute to the coupled state of skeletal muscle mitochon-
dria. However, this role requires further elucidation.
A reduced mitochondrial pool (particularly viable mito-
chondria) could also explain the decreased OXPHOS capacity
of dystrophic skeletal muscle in our study. We saw no geno-
type or muscle-specific differences in CS activity (a marker of
mitochondrial density) in our study; however, we did see dif-
ferential expression of ETC complex proteins in mdx RG and
WG whereby complex proteins generally decreased in RG but
increased in WG. This suggests a reduced respiratory capacity
despite increased/unchanged mitochondrial density in mdx
RG, in particular. We [23] and others [22, 62, 71] have previ-
ously reported this, highlighting that a reduced mitochondrial
functional and/or physical density does not account for the
decreased mitochondrial respiration associated with dystro-
phin-deficiency, but rather that themitochondrial pool is intrin-
sically defective. While NITR had no effect on complex ex-
pression in RG from either strain, most complexes (except
CIV), were upregulated in NITR-supplemented CON but not
NITR-supplementedmdxWG. In fact, the only observed effect
of NITR in WG that was consistent across strains was an in-
creased CS activity, and this was reproducible in the RG from
mdx but not CON mice. Our finding is curious as Ashmore
et al. [38] demonstrated that a high (1.4 mM) NITR diet in-
creases CS activity in red SOL muscle from healthy rats, al-
though a low (0.35 mM) and medium (0.7 mM) diet did not. In
context, we supplemented our mice with 1 mM NITR. Our
data thus suggest that there are variations in the response of
different fiber types to NITR-derived NO dosages, in which
type II fibers are more responsive to a lower NO concentration.
Irrespective of this, changes in mitochondrial CS activity and
electron transport chain complex expression induced by NITR
did not translate to improved mitochondrial respiration in ei-
ther CON or mdx muscles in our study.
We found in various respiratory states that NITR reduced
H2O2 production in mdx but not CON skeletal muscle. This
would immediately seem to be beneficial, as ROS production
is elevated in dystrophic muscle [57] and NO reduces oxida-
tive stress at the level of the ETS [72]. However, excessive NO
can lead to the generation of RNS in the presence of O2
–. In
addition to the inhibition of CIV, NO inhibits electron transfer
at CI and CIII of the ETS [73], producing O2
– anions that
interact with NO to produce ONOO– which can induce cellu-
lar damage [74]. In our study, we have demonstrated elevated
nitrotyrosine content in mdx TA muscles, which is consistent
with increased ONOO– production, and this was dramatically
exacerbated by NITR (2775% increase). Nitrotyrosine
labeling corresponded with an increased area of damage in
NITR-supplemented mdx TA sections. In previous studies,
NO donor therapy has been shown to reduce the area of dam-
age in dystrophic muscle, but as NO donors are typically giv-
en in combination with anti-inflammatories [29, 33], our data
suggest that the anti-inflammatory component of these co-
compounds is perhaps the more pertinent effector. NITR also
increased the proportion of centronucleated fibers inmdxmus-
cles, which has been previously observed with NO donors
[29, 30] and is reflective of an enhanced regenerative capacity
in response to NITR-induced damage. NO is a known stimu-
lator of satellite cell proliferation, which is crucial to skeletal
muscle regeneration following damage [75] and is notably
defective in dystrophin-deficient muscle [76, 77]. As dystro-
phic muscle is in a state of enhanced oxidative stress super-
fluous NITR-derived NO bioavailability appears detrimental
to dystrophic muscle by promoting excess ONOO– formation
which, in turn, may exceed antioxidant buffering capacity to
promote muscle damage and escalate pathology. This effect
may be more evident in predominantly white fast-twitch gly-
colytic muscles (such as TA) owing to the lower endogenous
antioxidant content and therefore NO handling capacity; how-
ever, further investigation is required to elucidate if this is true.
It is also possible that the absence of nNOS protein expres-
sion, its translocational capacity to deliver NO to specific in-
tracellular sites, and the metabolic modulatory effects it exerts
may account for the deleterious effect that NITR had on dys-
trophic muscle histopathology in our study, as breeding trans-
genic overexpressing nNOS mice with the mdx strain results
in significant improvements to dystrophic muscle architecture
[26, 27]. NITR therapy, however, might be beneficial for the
stimulation of satellite cell replication and dystrophic skeletal
muscle regeneration as we observed elevated presence of
DAPI-positive nuclei in NITR-treated mdx TA. While we
did not stain for Pax-7 (a satellite cell marker), we did label
CD45+ immune cell infiltrate and IgG deposition within the
muscle cross-sections—neither of these measures were affect-
ed by NITR SUPP, suggesting that the NITR-dependent in-
crease in nuclei content is most likely reflective of an en-
hanced satellite cell pool. Therefore, NITR therapy could be
beneficial especially if mitochondrial O2
– production could be
pharmacologically attenuated and RNS-induced damage
prevented (such as with antioxidant therapy).
In summary, our study is the first to demonstrate that an 8-
week supplementation regimen of NITR in drinking water
cannot overcome the metabolic dysfunction observed in the
mdx mouse model of DMD. We are the first to examine
contraction-induced GU in the mdxmodel and to demonstrate
that NITR supplementation reduces otherwise normal GU in
mdx muscles and cannot positively modulate mitochondrial
function. AlthoughNITR supplementation reduced mitochon-
drial H2O2 emission, it induced mitochondrial uncoupling in
RG, increased muscle fiber nitrosylation (and therefore
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ONOO– radicals), and promoted skeletal muscle damage. Our
data are consistent with recent literature linking NO to muscle
soreness [78]. Together this suggests that enhancing endoge-
nous NO production via exogenous NITR therapy is
contraindicative for the treatment of DMD. This is potentially
owing to the fact that there is no concomitant increase in
nNOS protein expression and its regulatory role over meta-
bolic flux control, and that excessive ROS promotes RNS
production which actually reduced NO bioavailability.
There were some limitations to our study that are worthy of
mention. In the first instance, we did not quantify cGMP
levels in EDL and SOL muscles, and thus cannot confirm that
in the presence of heightened O2
– production, NO is diverted
away from intracellular signaling pathways (i.e., cGMP pro-
duction, nucleus signaling of mitochondrial biogenesis) and
into RNS formation. This was because whole EDL and SOL
was required for our primary measure being radioactive GU,
and that our other tissues were not immediately snap frozen,
thus cGMP was heavily degraded beyond detectable levels.
Second, while simultaneous measurement of O2 flux and
H2O2 emission has previously been well characterized and
reported [50–52], a potential limitation of this assay is that
the supraphysiological chamber pO2 used to overcome O2
diffusion limitations of permeabilized muscle fiber prepara-
tions, may lead to nonphysiological rates of H2O2 emission
[79]. Therefore, it should be acknowledged that the H2O2
measured using the present assay may not completely recapit-
ulate in vivo mitochondrial ROS emission rates.
In conclusion, our data are in stark contrast to previous
findings of significant improvements in the dystrophic condi-
tion following NO donor therapy, and in patients with Becker
muscular dystrophy following nitrite supplementation, sug-
gesting that long-term NITR/NO supplementation requires
better characterization, particularly in conditions of height-
ened oxidative and/or metabolic stress such as in DMD.
While the precise myopathological mechanisms of NITR has
not been fully elucidated in the present study, our data are of
particular importance considering NITR therapy is currently
in clinical trials for the treatment of patients with DMD.
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